Dorsavi Ltd. · ASX:DVL
Dorsavi — Investor Presentation (July 2022)
25 slides from Dorsavi's investor presentation, Jul 29, 2022
Slide 1: Investor presentation
Investor presentation July 2022
Slide 2: Executive Summary
Executive Summary World class • Revenue generating medical device company commercialising innovative motion analysis technologies trusted by leading technology international organisations including Medtronic, QBE, Boeing and many more. Robust business • Product-led business with >90% gross margins -
Slide 3: World class technology
257/408 = 63% Symmetry and balance World class technology WY dorsaVi
Slide 4: Leading provider across two major markets (clinical and workplace)
Leading provider across two major markets (clinical and workplace) Unique, validated and proven technology trusted by leading institutions globally Used and validated by leading institutions1 Leading technology Wearable sensors that measure quality of movement and muscle activity in workplace and cl
Slide 5: Robust business model
Robust business model 5
Slide 6: Product led high margin business
Product led high margin business Gross margins over 90% sustained through product-led business model Gross margin (%)1 1 Commitment to product-led model Target gross margins >90% 95% 91% 91% Facilitated investment in technological 90% 2 82% development COVID impact to site access 3 Building increase
Slide 7: Stable revenue providing a platform for growth
Stable revenue providing a platform for growth Sustained growth with enhanced sales and marketing approach for new product Sales revenue (A$m) $2.4m $2.0m Positive outlook for FY23 underpinned by: $1.9m Focus on recurring revenue has built a stable base from which to grow Enhanced sales and mark
Slide 8: Lean expense management towards a sustainable business
Lean expense management towards a sustainable business Investments made in product and data security for future benefits Operating expenses (A$m)1 Includes ISO27001 certification $6.8m costs, AMI2 product development and launch costs $5.1m $5.0m $4.5m See slide 9 ~$3.0m FY19A FY20A FY21A FY22A3 FY23
Slide 9: Further reductions to cost base expected
Further reductions to cost base expected Plan in place to further minimise expenditure with many initiatives already complete 1 Operating expenses bridge (A$m)1 Technology investment driving process optimisation (e.g. data collection and entry, remote working, etc.) 1 $4.5m Enhanced sales and cu
Slide 10: Clear and validated strategy
Clear and validated strategy 10
Slide 11: Clear and validated strategy - valuable target markets
Clear and validated strategy - valuable target markets Targeting two key valuable markets with attractive growth propositions Workplace Clinical Selling sensors direct to physical therapists, Contracts with tier one enterprise customers backed by health insurance Aim to reduce workplace injuri
Slide 12: Workplace market - direct
Workplace market - direct Proven to help large enterprise customers reduce workplace injuries Targeting tier one customers… … with proven results Helping companies to reduce workplace injuries, improve productivity and create a lasting health and 12 month pilot program led to >84% safety culture red
Slide 13: Workplace market – strategic customers
Workplace market – strategic customers Partnered with insurance companies to reduce premiums and de-risk new client wins QBE strategic relationship Large upside with network effect Strategic relationship with QBE More companies sign Initial relationship with QBE in 2020 aiming Australia directly w
Slide 14: Clinical market - direct
Clinical market - direct Provision of digital health tools to physical therapists Over 300 dorsaVi clinical products in the US1 1 14 18 1 2 4 11 8 4 5 Capture novel & clinically Assess the effectiveness of 12 26 21 1 relevant data insights treatment programs 3 18 9 2 10 3 3 16 30 21 11 1 7 16 2 13 9
Slide 15: Multiple growth pathways
Front Plank 25/30 ny ~ ~~ 52/60 R Side Plank R Leg Hop PI y 40/48 7 R Ankle Lunge Multiple growth pathways y dorsaVi 15
Slide 16: Robust clinical market drives revenue growth
Robust clinical market drives revenue growth Revenue growth led by US clinical market Sales revenue (A$m) Revenue growth driven by several factors Clinical market Clinical revenue led by the US +42% The US contributes to over 70% of clinical market revenues $1.6m Use of product is reimbursed Pro
Slide 17: Expanded pipeline of workplace customers
Expanded pipeline of workplace customers Sales pipeline expanded and new deals signed as ‘return-to-work’ momentum continues Value of new workplace contracts won (A$k) +23% Select recent client wins $397k $322k Four new development contracts with Boeing signed, expected to last ~12 months H1 FY22A1
Slide 18: Upgrades to best-selling Athletic Movement Index (AMI) product
Upgrades to best-selling Athletic Movement Index (AMI) product Technology and product enhancements unlock exciting growth pathways AMI product Features and benefits Product enhancements Assessment time reduced by 50% Superior value proposition ISO 27001 compliant Enhanced functionality and data secu
Slide 19: Significant upside potential – industry tailwinds
Significant upside potential – industry tailwinds Primed to capitalise on continued return to work and healthcare digitisation trends Return to work Digital health Personalised care Client activities are resuming at Increasing digitisation across the Increased demand for personalised several sites w
Slide 20: Significant upside potential
Significant upside potential dorsaVi is currently trading at a lower revenue multiple compared to its peers Market Cap / FY21 Sales revenue multiple Select ASX listed peers 19.0x 12.3x 11.7x 9.0x 7.9x 8.3x 3.3x 2.3x Market cap (A$m)1 4.3 12.9 140.1 31.3 45.1 97.9 71.0 71.5 Revenue (A$m)2 1.9 3.9 17.
Slide 21: Appendix
Appendix Vv dorsaVi 21
Slide 22: Corporate overview
Corporate overview Board and management Financial information Share price (26-July-22) $0.014 Andrew Ronchi Director & Chief Executive Officer 52-week trading range (low / high) $0.009 / $0.030 Shares on issue 356.5m Troy Di Domenico Chief Financial Officer Market capitalisation $5.0m Cash (30-Jun-2
Slide 23: Important information and disclaimer
Important information and disclaimer Not financial product advice or offer This presentation does not constitute an offer of securities or investment, legal, taxation or other advice and the presentation does not take into account your investment objectives, financial situation or particular needs.
Slide 24: Important information and disclaimer
Important information and disclaimer Forward-Looking Statements This document contains or may contain forward-looking statements that are based on dorsaVi management’s beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating p
Slide 25: Contact us
Contact us Company Andrew Ronchi Director and CEO T: +61 417 882 267 E: ar@dorsaVi.com Investors Dean Dribbin Vesparum Capital T: +61 3 8582 4800 E: dorsaVi@vesparum.com Unit 3, 11-13 Milgate Street South Oakleigh, Vic, 3167 www.dorsavi.com